Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.15)
# 3,835
Out of 5,182 analysts
87
Total ratings
36.54%
Success rate
-15.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMCL Omnicell | Maintains: Overweight | $52 → $55 | $37.63 | +46.16% | 19 | Apr 23, 2026 | |
| PHR Phreesia | Maintains: Overweight | $30 → $25 | $9.62 | +159.88% | 2 | Mar 26, 2026 | |
| CTEV Claritev | Maintains: Equal-Weight | $30 → $22 | $24.22 | -9.17% | 3 | Mar 19, 2026 | |
| HCAT Health Catalyst | Downgrades: Equal-Weight | $5 → $1 | $1.37 | -27.01% | 8 | Mar 18, 2026 | |
| VEEV Veeva Systems | Maintains: Overweight | $333 → $317 | $160.45 | +97.57% | 10 | Mar 5, 2026 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $7 → $3.5 | $2.28 | +53.51% | 9 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $8 → $6 | $5.85 | +2.56% | 4 | Feb 26, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $41 → $36 | $25.70 | +40.08% | 2 | Feb 19, 2026 | |
| DOCS Doximity | Maintains: Overweight | $55 → $45 | $24.66 | +82.48% | 14 | Feb 6, 2026 | |
| HNGE Hinge Health | Initiates: Overweight | $68 | $45.03 | +51.01% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $17 | $14.72 | +15.49% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $6.14 | +46.58% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $125 | $83.47 | +49.75% | 9 | Feb 26, 2025 |
Omnicell
Apr 23, 2026
Maintains: Overweight
Price Target: $52 → $55
Current: $37.63
Upside: +46.16%
Phreesia
Mar 26, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $9.62
Upside: +159.88%
Claritev
Mar 19, 2026
Maintains: Equal-Weight
Price Target: $30 → $22
Current: $24.22
Upside: -9.17%
Health Catalyst
Mar 18, 2026
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $1.37
Upside: -27.01%
Veeva Systems
Mar 5, 2026
Maintains: Overweight
Price Target: $333 → $317
Current: $160.45
Upside: +97.57%
GoodRx Holdings
Mar 4, 2026
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.28
Upside: +53.51%
Teladoc Health
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $5.85
Upside: +2.56%
Waystar Holding
Feb 19, 2026
Maintains: Overweight
Price Target: $41 → $36
Current: $25.70
Upside: +40.08%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $55 → $45
Current: $24.66
Upside: +82.48%
Hinge Health
Jan 9, 2026
Initiates: Overweight
Price Target: $68
Current: $45.03
Upside: +51.01%
Jan 9, 2026
Initiates: Equal-Weight
Price Target: $17
Current: $14.72
Upside: +15.49%
Nov 5, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $6.14
Upside: +46.58%
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $83.47
Upside: +49.75%